abrdn plc Grows Holdings in DaVita Inc. (NYSE:DVA)

abrdn plc increased its position in DaVita Inc. (NYSE:DVA - Free Report) by 17.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 168,316 shares of the company's stock after acquiring an additional 24,966 shares during the period. abrdn plc owned about 0.18% of DaVita worth $17,633,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DVA. PNC Financial Services Group Inc. raised its stake in shares of DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company's stock worth $1,426,000 after purchasing an additional 153 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new position in DaVita during the 4th quarter valued at about $2,831,000. Raymond James & Associates lifted its position in DaVita by 135.2% during the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company's stock valued at $3,601,000 after purchasing an additional 19,759 shares during the period. Nisa Investment Advisors LLC boosted its holdings in DaVita by 27.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company's stock worth $5,341,000 after purchasing an additional 11,097 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in DaVita by 2,178.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company's stock worth $11,379,000 after purchasing an additional 103,856 shares during the period. 90.12% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider James O. Hearty sold 26,164 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares in the company, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael David Staffieri sold 29,488 shares of DaVita stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the sale, the chief operating officer now owns 37,687 shares of the company's stock, valued at approximately $4,515,279.47. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock valued at $16,551,071 over the last three months. 1.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. StockNews.com downgraded DaVita from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 16th. Truist Financial boosted their price target on DaVita from $130.00 to $135.00 and gave the company a "hold" rating in a research note on Tuesday, February 20th. UBS Group increased their price objective on shares of DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. Barclays assumed coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an "equal weight" rating and a $133.00 target price for the company. Finally, TheStreet upgraded shares of DaVita from a "c+" rating to a "b-" rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $118.50.

DaVita Price Performance

DaVita stock traded up $0.03 during midday trading on Thursday, reaching $132.77. 519,286 shares of the stock traded hands, compared to its average volume of 802,587. The stock has a market cap of $11.64 billion, a P/E ratio of 17.94, a PEG ratio of 1.19 and a beta of 1.04. The stock's fifty day moving average is $131.63 and its 200-day moving average is $110.00. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $141.54.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.53 by $0.34. The firm had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. During the same quarter last year, the firm earned $1.11 EPS. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities research analysts anticipate that DaVita Inc. will post 9.23 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.